<DOC>
	<DOCNO>NCT02401048</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability combination treatment ibrutinib MEDI4736 patient relapse refractory lymphoma .</brief_summary>
	<brief_title>A Multi-Center Study Ibrutinib Combination With MEDI4736 Subjects With Relapsed Refractory Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologically document relapsed refractory diffuse large Bcell lymphoma ( DLBCL ) follicular lymphoma ( FL ) Measurable disease sit CT scan ( &gt; 1.5 cm long dimension ) Adequate hematologic function : 1 . Absolute Neutrophil Count &gt; 1500 cells/mm3 2 . Platelets &gt; 50000 cells/mm3 3 . Hemoglobin &gt; 8.0 g/dL Adequate hepatic renal function : 1 . AST ALT ≤2.5 x ULN 2 . Bilirubin ≤1.5 x ULN 3 . Estimated creatinine clearance ( CockcroftGault ) &gt; 40 mL/min ECOG 0 1 Received prior therapy : ibrutinib , BTK inhibitor and/or antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , CTLA4 antibody Requires treatment prophylaxis strong cytochrome P450 ( CYP ) 3A inhibitor Primary CNS lymphoma evidence CNS involvement lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>